Search

Displaying results 3041 - 3050 of 10000 in total
  1. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … Acipimox is a niacin derivative used as a hypolipidemic agent.

  2. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    or/and that fill an unmet medical need based on a surrogate endpoint. … [L10241] In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  3. Drug

    Tenecteplase

    go.drugbank.com/drugs/DB00031
    ApprovedInvestigational

    296-299 in the protease domain. … It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids

  4. Drug

    SGS-742

    go.drugbank.com/drugs/DB05010
    Investigational

    SGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.

    Synonyms: (3-Aminopropyl)(n-butyl)phosphinic acidCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. … Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke.

    Products: TICLOPIDIN AL 250
  6. Drug

    Dihydro-alpha-ergocryptine

    go.drugbank.com/drugs/DB11274
    Approved

    Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. … Alpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049]

  7. Drug

    Sulopenem etzadroxil

    go.drugbank.com/drugs/DB16335
    ApprovedInvestigational

    Sulopenem etzadroxil is a prodrug of the penem antibacterial [sulopenem]. Like other beta-lactam antibacterials, it is a time-dependent inhibitor of bacterial cell wall synthesis. … [L51858] It is administered in combination with [probenecid] in order to increase antibiotic exposure.[L51768]

  8. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. … [A251385] PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme [L37564] expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells

  9. Drug

    Clocortolone

    go.drugbank.com/drugs/DB00838
    Approved

    Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.

    Categories: Corticosteroids, Moderately Potent (Group II)
  10. Drug

    Acetyl sulfisoxazole

    go.drugbank.com/drugs/DB14033
    ApprovedVet approved

    Sulfisoxazole acetyl is an ester of _sulfisoxazole_, a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial activity. … This process causes an inhibition of bacterial folic acid synthesis and de novo synthesis of purines and pyrimidines, resulting in cell growth arrest and cell death [L2788].